SMAD2 and cancer: Recently, PSPC1 upregulation in multiple cancer types was demonstrated to play as a contextual determinant of pro-metastatic switch via hijacking the Smad2/3 from targeting pro-apoptotic genes in normal cells reprogrammed to activate TGF-β1 autocrine signaling and the pro-metastatic target genes in cancer cells to facilitate tumor progression [11].